Undervalued Biotechnology Stocks on TSE July 2023

July 15, 2023

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

Toronto Stock Exchange

The Toronto Stock Exchange (TSE) is a stock exchange located in Toronto, Ontario, Canada. It is the 10th largest exchange in the world and the third largest in North America based on market capitalization.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
AEZS AEterna Zentaris 3.65 7.15 95.97 555 18 0.00 0.0
ATE Antibe Therapeutics 0.45 0.78 73.94 24641 24 0.00 0.0
RVX Resverlogix 0.10 0.17 73.45 104800 25 0.00 0.0
PMN ProMIS Neurosciences 3.65 6.02 64.82 4070 31 0.00 0.0
MDNA Medicenna Therapeutics 0.66 0.96 45.17 17223 43 0.00 0.0
IN InMed Pharmaceuticals 4.19 5.36 27.99 21307 26 0.00 0.0
APLI Appili Therapeutics 0.04 0.04 26.17 95916 4 0.00 0.0
APS Aptose Biosciences 5.88 7.33 24.73 956 36 0.00 0.0
TH Theratechnologies 1.12 1.36 21.30 18107 108 0.00 0.0
IPCI IntelliPharmaCeutics Intl 0.07 0.07 13.02 8669 2 0.00 0.0
All data provided as at market close July 12, 2023.

Company Details

AEterna Zentaris

AEZS:TSX

Close Price

3.65

Our Valuation

7.15

% Difference

95.97

Market Cap ($M)

18

P/E Ratio

0.0

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada.

Access the stockcalc valuation


Antibe Therapeutics

ATE:TSX

Close Price

0.45

Our Valuation

0.78

% Difference

73.94

Market Cap ($M)

24

P/E Ratio

0.0

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain.

Access the stockcalc valuation


Resverlogix

RVX:TSX

Close Price

0.10

Our Valuation

0.17

% Difference

73.45

Market Cap ($M)

25

P/E Ratio

0.0

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Access the stockcalc valuation


ProMIS Neurosciences

PMN:TSX

Close Price

3.65

Our Valuation

6.02

% Difference

64.82

Market Cap ($M)

31

P/E Ratio

0.0

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Medicenna Therapeutics

MDNA:TSX

Close Price

0.66

Our Valuation

0.96

% Difference

45.17

Market Cap ($M)

43

P/E Ratio

0.0

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors.

Access the stockcalc valuation


InMed Pharmaceuticals

IN:TSX

Close Price

4.19

Our Valuation

5.36

% Difference

27.99

Market Cap ($M)

26

P/E Ratio

0.0

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Access the stockcalc valuation


Appili Therapeutics

APLI:TSX

Close Price

0.04

Our Valuation

0.04

% Difference

26.17

Market Cap ($M)

4

P/E Ratio

0.0

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Access the stockcalc valuation


Aptose Biosciences

APS:TSX

Close Price

5.88

Our Valuation

7.33

% Difference

24.73

Market Cap ($M)

36

P/E Ratio

0.0

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Access the stockcalc valuation


Theratechnologies

TH:TSX

Close Price

1.12

Our Valuation

1.36

% Difference

21.30

Market Cap ($M)

108

P/E Ratio

0.0

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

Access the stockcalc valuation


IntelliPharmaCeutics Intl

IPCI:TSX

Close Price

0.07

Our Valuation

0.07

% Difference

13.02

Market Cap ($M)

2

P/E Ratio

0.0

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
AEterna Zentaris and Antibe Therapeutics are the most undervalued Biotechnology stocks on the TSE. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-july-2023
AEterna Zentaris $AEZS and Antibe Therapeutics $ATE are the most undervalued Biotechnology stocks on the #TSE. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-july-2023
AEterna Zentaris and Antibe Therapeutics are the most undervalued Biotechnology stocks on the TSE. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tse-july-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.